key: cord-0269446-1wkpkh84 authors: Walters, Jewell N.; Schouest, Blake; Patel, Ami; Reuschel, Emma L.; Schultheis, Katherine; Parzych, Elizabeth; Maricic, Igor; Gary, Ebony N.; Purwar, Mansi; Andrade, Viviane M.; Doan, Arthur; Elwood, Dustin; Eblimit, Zeena; Nguyen, Brian; Frase, Drew; Zaidi, Faraz I.; Kulkarni, Abhijeet; Generotti, Alison; Kim, J Joseph; Humeau, Laurent M.; Ramos, Stephanie J.; Smith, Trevor R.F.; Weiner, David B.; Broderick, Kate E. title: Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates date: 2021-10-29 journal: bioRxiv DOI: 10.1101/2021.10.27.466163 sha: f8a68a38fa517776241f555dd35ce16d23c91784 doc_id: 269446 cord_uid: 1wkpkh84 The enhanced transmissibility and immune evasion associated with emerging SARS-CoV-2 variants demands the development of next-generation vaccines capable of inducing superior protection amid a shifting pandemic landscape. Since a portion of the global population harbors some level of immunity from vaccines based on the original Wuhan-Hu-1 SARS-CoV-2 sequence or natural infection, an important question going forward is whether this immunity can be boosted by next-generation vaccines that target emerging variants while simultaneously maintaining long-term protection against existing strains. Here, we evaluated the immunogenicity of INO-4800, our synthetic DNA vaccine candidate for COVID-19 currently in clinical evaluation, and INO-4802, a next-generation DNA vaccine designed to broadly target emerging SARS-CoV-2 variants, as booster vaccines in nonhuman primates. Rhesus macaques primed over one year prior with the first-generation INO-4800 vaccine were boosted with either INO-4800 or INO-4802 in homologous or heterologous prime-boost regimens. Both boosting schedules led to an expansion of antibody responses which were characterized by improved neutralizing and ACE2 blocking activity across wild-type SARS-CoV-2 as well as multiple variants of concern. These data illustrate the durability of immunity following vaccination with INO-4800 and additionally support the use of either INO-4800 or INO-4802 in prime-boost regimens. The enhanced transmissibility and immune evasion associated with emerging SARS-CoV-2 18 variants demands the development of next-generation vaccines capable of inducing superior 19 protection amid a shifting pandemic landscape. Since a portion of the global population harbors been the primary target of vaccine development for each of these viruses [1] . Although the rollout 40 of the EUA vaccines has been underway for several months, global distribution of these vaccines 41 has fallen along entrenched socioeconomic lines, leaving many low-and middle-income countries 42 with inadequate supply [2] . For successful global coverage, many more vaccines will be needed. 43 The rapid expansion of SARS-CoV-2 variants of concern (VOC) has corresponded with a 44 reduction in neutralizing antibody activity in convalescent and vaccinated individuals, suggesting 45 that emerging mutations observed in some lineages are associated with immune escape [3] [4] [5] [6] [7] . 46 Alarmingly, the Beta (B.1.351) variant has demonstrated a reduced sensitivity to neutralizing sera 47 from convalescent and immunized individuals [7] . Recently In the current study, we investigated the durability and memory recall of antigen-specific SARS- CoV-2 responses in a cohort of non-human primates that were initially primed with the first- 304 Blood was collected from each study animal into sodium citrate cell preparation tubes (CPT, BD 305 Biosciences). The tubes were centrifuged to separate plasma and lymphocytes, according to the 306 manufacturer's protocol. Samples from the prime immunization were transported by same-day 307 shipment on cold-packs from Bioqual to The Wistar Institute, and boost samples were shipped 308 overnight to Inovio Pharmaceuticals for PBMC isolation. PBMCs were washed, and residual red 309 blood cells were removed using ammonium-chloride-potassium (ACK) lysis buffer. Cells were 310 counted using a ViCell counter (Beckman Coulter) and resuspended in RPMI 1640 (Corning), 311 supplemented with 10% fetal bovine serum (Seradigm), and 1% penicillin/streptomycin (Gibco). Fresh cells were then plated for IFNγ ELISpot assay to detect cellular responses. For prime immunization samples, ninety-six well immunosorbent plates (NUNC) were coated with 326 1ug/mL recombinant SARS-CoV-2 S1+S2 ECD protein (Sino Biological 40589-V08B1), S1 The Current and Future State of Vaccines, Antivirals 409 and Gene Therapies Against Emerging Coronaviruses How COVID vaccines are being divvied up around the world 501Y.V2 escapes neutralization by South African COVID-19 donor plasma Antibody resistance of SARS-CoV-2 variants 417 Multiple SARS-CoV-420 2 variants escape neutralization by vaccine-induced humoral immunity mRNA-1273 vaccine induces 424 neutralizing antibodies against spike mutants from global SARS-CoV-2 variants Sensitivity of infectious 427 SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies Covid-19 Vaccines against the B.1.617.2 (Delta) Variant Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-435 Immunogenicity of a DNA vaccine 438 candidate for COVID-19 Vaccine development for emerging virulent infectious diseases Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral 445 One or two dose 448 regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease 449 burden in nonhuman primate challenge model Intradermal-delivered DNA 452 vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model Safety and 459 immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, 460 blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure Prime-boost vaccine strategy against viral infections: 466 Mechanisms and benefits Heterologous prime-boost vaccination Broad and potent immune 472 responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy 473 adults in Tanzania Safety and immunogenicity 476 of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a 477 randomized clinical trial Electroporation delivery of DNA vaccines: prospects for success Epub 2011/05/03 Comparative 483 analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or 484 plasmid DNA in rhesus macaques COVID-19 vaccine 487 BNT162b1 elicits human antibody and TH1 T cell responses Helper Cell Biology: A Decade of Discovery and Diseases Nucleoside-modified 493 mRNA vaccines induce potent T follicular helper and germinal center B cell responses A single dose of 497 the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses Epub 2021/06/17 Projecting the transmission dynamics of 501 SARS-CoV-2 through the postpandemic period How the pandemic might play out in 2021 and beyond Immunological memory to SARS-CoV-506 2 assessed for up to 8 months after infection Rapid generation of 509 durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence Epub 2021/01/15 Durability of 513 Responses after SARS-CoV-2 mRNA-1273 Vaccination SARS-CoV-2 vaccines 516 elicit durable immune responses in infant rhesus macaques SARS-CoV-2 519 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors 520 and vaccinees INO-4800 DNA Vaccine 523 Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants Covid-19 Vaccine against the B.1.351 Variant Vaccine against the B.1.351 Variant Preliminary Analysis of Safety and 532 Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster Safety and immunogenicity 538 of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA 539 COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial Heterologous prime-boost 543 vaccination with ChAdOx1 nCoV-19 and BNT162b2 Heterologous ChAdOx1 nCoV-546 19 and mRNA-1273 Vaccination SARS-CoV-2 DNA Vaccine 549 INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Naturally enhanced 552 neutralizing breadth against SARS-CoV-2 one year after infection Maturation and 556 persistence of the anti-SARS-CoV-2 memory B cell response Persistence of 560 functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG Neutralizing antibody 563 levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Activity Elicited by mRNA-1273 Vaccine BNT162b2 vaccine 569 induces neutralizing antibodies and poly-specific T cells in humans Safety and 572 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary Spike-specific circulating T follicular helper cell 576 and cross-neutralizing antibody responses in COVID-19-convalescent individuals Humoral and circulating follicular 579 helper T cell responses in recovered patients with COVID-19 Evaluation of the 582 mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates